The phase 3 EPCOR FL-1 trial showed that adding epcoritamab to the lenalidomide/rituximab (R-squared) backbone profoundly improved progression-free survival in relapsed follicular lymphoma. Presented as the most important FL abstract at ASH, this result is expected to establish a new standard of care in this setting.

A novel trial design used mosinutuzumab monotherapy first in frontline follicular lymphoma, adding lenalidomide only for patients without a complete response. This adaptive approach successfully spared about two-thirds of patients from the added toxicities of lenalidomide while still achieving very high overall efficacy.

Long-term follow-up from the Epcor-NHL1 trial reveals that epcoritamab monotherapy can produce highly durable complete responses in relapsed/refractory large B-cell lymphoma. With some patients remaining in remission for over 54 months, the therapy is positioned as a potential curative option in this setting.

Beyond approving the triplet combination, the positive Epcor FL1 trial data had a significant ripple effect. It solidified the drug's overall profile, leading to the conversion of its prior provisional (accelerated) approvals for monotherapy in follicular lymphoma and DLBCL into full, traditional approvals.

In follicular lymphoma, the treatment goal is durable remission with manageable toxicity, not necessarily a cure. Therefore, clinicians frequently prefer using a bispecific antibody first, reserving the more complex and toxic CAR-T cell therapy for transformed disease or after a bispecific fails.

Not all CD20-targeting bispecifics can be combined with rituximab. Mosunetuzumab binds the same epitope, causing competition. However, glofitamab and epcoritamab bind different epitopes, allowing for logical and potentially synergistic combinations with rituximab-based regimens.

As CAR-T cell therapies are increasingly adopted for second-line treatment of large cell lymphoma, epcoritamab is solidifying its role as a critical, potentially curative replacement option in the third-line setting. This establishes a clear sequential treatment pathway for patients who continue to relapse.

In the IN-MIND trial for relapsed follicular lymphoma, the tafasitamab-lenalidomide-rituximab arm had zero cases of histologic transformation to a more aggressive lymphoma. This contrasts with nine cases in the control arm, suggesting the CD19-targeting antibody may eradicate precursor cells responsible for this dreaded complication.

The regimen's profound success in relapsed/refractory patients is not an endpoint, but a launchpad. It provides the rationale for the ongoing Epcor FL2 trial, which directly challenges standard chemoimmunotherapy and could establish a chemotherapy-free, bispecific-based combination as the new first-line standard of care.